Salute in Horizon 2020: Giornata Nazionale di Lancio dei bandi … · 2013. 12. 5. · CM1106 –...
Transcript of Salute in Horizon 2020: Giornata Nazionale di Lancio dei bandi … · 2013. 12. 5. · CM1106 –...
Collaborazione tra Università e Industria in un progetto europeo "Innovation 2" del Settimo Programma Quadro
(FP7): THINPAD
Salute in Horizon 2020:
Giornata Nazionale di Lancio dei bandi 2014-15
- Maurizio Botta -
Università degli Studi di Siena
3 Dicembre 2013, Roma
Prof. Maurizio Botta
- 1974. Laurea cum laude in Chemistry at University of Rome - 1979. PhD Università del New Brunswick, Canada (Prof. Wiesner) - 1980-1985 Researcher at University of Rome (Prof. Nicoletti) - 1985-87. Post-doc at Montreal (Prof. Hanessian) - 1987 Professore Associato, University of Siena -2000 Professore Ordinario, University of Siena -- Member Editorial board of ACS J. Med. Chem., ChemMedChem -- Adjunt Professor Sbarro Institute for Cancer Research and Molecular Medicine Temple University, Philadelphia, USA
Google scholar CITATION REPORT
Number of publications: 430 Number of Patents: 15
Number of citations: 5917 h-index: 37
i10-index: 210
University of Siena
Dipartimento di Biotecnologie, Chimica e Farmacia
-Polo Scientifico San Miniato –
Via Aldo Moro 2 53100 - SIENA, Italy
The Dipartimento di Biotecnologie, Chimica e Farmacia of Siena University was
created in 1982. It is situated within the Scientific Area of the San Miniato
University Campus, where the majority of the scientific and educational
institutions are housed and where to it moved in 1999 from its previous location
at the centre of Siena.
Disease
selection
Gene to
function
Function
to Target
Target to
Hit
Hit to
Lead
Lead
optimisa-
tion
Pre-dev.
compound Phase I Phase II Phase III Phase IV
milligrams grams kilos
Combined application of Molecular Modeling , Combinatorial Chemistry and Analytical
Techniques to Speed-up the Lead Discovery Process
Molecular Modeling
Primary libraries
Focused libraries
Combinatorial Chemistry
Solid-phase synthesis
Parallel synthesis
Asymmetric synthesis
Biotransformation using enzymes
Microwave-assisted synthesis
Expertise
Overview of the Botta’s Research Group
Molecular Modeling
Organic Synthesis
Design and Synthesis of Hit Compounds “Hit to Lead” Optimization Theoretical Study on Target Proteins ADMET properties …
Virtual Screening Pharmacophore modeling Molecular Dynamics ADMET prediction …
Microwave-assisted Click-chemistry Natural compounds synthesis Combinatorial chemistry …
Analytical Chemistry & Toxicology
ADMET properties Membrane permeation Drug metabolism (liver) …
Main Research Areas
Cancer
HIV/AIDS -Reverse Transcriptase -Integrase -ENTRY -NCp7
Tuberculosis -Zmp1 -PtpB
-pyrazoles -pyrazolopyrimidin-7-ones
Kinetoplastid diseases -T. cruzi Tryp.Reductase
-L. infantum Tryp.Reductase -T. cruzi G6PDH -T. cruzi CYP51
Fungal/bacterial infections -macrocyclic amidoguanidines -linear guanidines
Leukemia Neuroblastoma
Medulloblastoma ……..
Infectious disorders
EU Projects involvement
TRIoH Targeting Replication and Integration of HIV- 6th Framework
Programme LSHB CT-2003-503480, from 01/2004 to 06/2007;
ExCellENT-HIT Exploiting Cellular Transport of Nuclear Transcripts as HIV
Innovative Therapy LSHP-CT-2006-037257 11/2006-10/2008;
THINC Targeting hiv integration co-factors, targeting cellular proteins during
nuclear import or integration of hiv
7th Framework Programme-HEALTH-2007-2.3.2-1 from 03/2008 to 02/2012;
CHAARM Combined Highly Active Anti-retroviral Microbicides –
7th Framework Programme 242135 from 01/2010 to 01/2015;
FLUCURE (HEALTH.2010.2.3.3-4 Novel therapeutics against influenza.
FP7-INFLUENZA-2010), Project reference: 259972
from 01/2010 to 01/2014
Design of MSAAs. Research Training Network (HPRN-CT-2000-
00018) “Design and Synthesis of Novel Paclitaxel (Taxol®) Mimics
Using a Common Pharmacophore Model for Microtubule-Stabilizing
Agents (MSAAs)” 09/2000 – 08/2004
COST Action Involvment
CM0602 – Inhibitors of Angiogenesis: Design, Synthesis and
Biological Exploration (ANGIOKEM).
CM0801 – New Drugs for Neglected Diseases
CM0804 – Chemical Biology with Natural Products.
CM1106 – Chemical Approaches to Targeting Drug Resistance in
Cancer Stem Cells.
CM1307 – Targeted Chemoterapy Towards Disease caused by
endoparasites.
FP7-HEALTH-2013
Proposal full title: Imaging technologies for detection, diagnosis and therapy of neuroblastoma Proposal acronym: ImagTechNB Work programme topics addressed: HEALTH.2013.1.2-1: Development of imaging technologies for therapeutic interventions in rare diseases Coordinator: Università degli Studi di Siena (Prof. Maurizio Botta) Writing collaborator: Dr. Giorgio Maccari Proposal full title: Targeting Kinetoplastid Diseases Proposal acronym: TarKinD Work programme topics addressed: HEALTH.2013.2.3.4-2: Drug development for neglected parasitic diseases Coordinator: Università degli Studi di Siena (Prof. Maurizio Botta) Writing collaborator: Dr. Francesca Moraca Proposal full title: Targeting the HIV-1 Nucleocapsid Protein to Fight Antiretroviral Drug Resistance Proposal acronym: THINPAD Work programme topics addressed: HEALTH.2013.2.3.1-1: Drugs and vaccines for infections that have developed or are at risk of developing significant anti-microbial resistance Coordinator: Università degli Studi di Siena (Prof. Maurizio Botta) Writing collaborator: Dr. Mattia Mori
STAGE 1
Proposal full title: Imaging technologies for detection, diagnosis and therapy of neuroblastoma Proposal acronym: ImagTechNB Work programme topics addressed: HEALTH.2013.1.2-1: Development of imaging technologies for therapeutic interventions in rare diseases Coordinator: Università degli Studi di Siena (Prof. Maurizio Botta) Writing collaborator: Dr. Giorgio Maccari Proposal full title: Targeting Kinetoplastid Diseases Proposal acronym: TarKinD Work programme topics addressed: HEALTH.2013.2.3.4-2: Drug development for neglected parasitic diseases Coordinator: Università degli Studi di Siena (Prof. Maurizio Botta) Writing collaborator: Dr. Francesca Moraca Proposal full title: Targeting the HIV-1 Nucleocapsid Protein to Fight Antiretroviral Drug Resistance Proposal acronym: THINPAD Work programme topics addressed: HEALTH.2013.2.3.1-1: Drugs and vaccines for infections that have developed or are at risk of developing significant anti-microbial resistance Coordinator: Università degli Studi di Siena (Prof. Maurizio Botta) Writing collaborator: Dr. Mattia Mori
STAGE 2
Proposal full title: Imaging technologies for detection, diagnosis and therapy of neuroblastoma Proposal acronym: ImagTechNB Work programme topics addressed: HEALTH.2013.1.2-1: Development of imaging technologies for therapeutic interventions in rare diseases Coordinator: Università degli Studi di Siena (Prof. Maurizio Botta) Proposal full title: Targeting Kinetoplastid Diseases Proposal acronym: TarKinD Work programme topics addressed: HEALTH.2013.2.3.4-2: Drug development for neglected parasitic diseases Coordinator: Università degli Studi di Siena (Prof. Maurizio Botta) Writing collaborator: Dr. Francesca Moraca Proposal full title: Targeting the HIV-1 Nucleocapsid Protein to Fight Antiretroviral Drug Resistance Proposal acronym: THINPAD Work programme topics addressed: HEALTH.2013.2.3.1-1: Drugs and vaccines for infections that have developed or are at risk of developing significant anti-microbial resistance Coordinator: Università degli Studi di Siena (Prof. Maurizio Botta) Writing collaborator: Dr. Mattia Mori
Targeting the HIV-1 Nucleocapsid Protein to fight
Antiretroviral Drug Resistance
THINPAD website is online http://www.thinpad.unisi.it/index.html
THINPAD Partners
8th IRNCS – Barcelona 2011 9th IRNPAS – Montreal 2013
SMEs in THINPAD
-IRBM Science Park (http://www.irbm.it/) -ViroStatics (http://www.virostatics.com/)
• Active collaborations with SMEs, even before THINPAD
HIV
Cancer
Other disease
• SMEs participated to writing and editing the THINPAD proposal
• The THINPAD Business Plan has been elaborated by SMEs and
discussed with other THINPAD parties
THINPAD Budget – SMEs oriented
Academic partner Academic partner Academic partner
SME partner SME partner
INNOVATION-2 SMEs shall request
> 50% of total budget
THINPAD Management & Decision Making Structure
THINPAD WPs Overview
THINPAD Coordination
Research activity WP2 to WP6
Two coordination workpackages strictly connected with research workpackages
THINPAD Research Work Plan – Step1: LEAD SELECTION
THINPAD Research Work Plan – Step2: preclinical studies
THINPAD Business Plan - highlights
• completion of “first-in-man” enabling studies
• Phase 1 Clinical study
• manufacturing, commercialization
• marketing rights
Out-licensing to Pharmaceutical
Companies
[starting from the end of 2017]
Managed by THINPAD SMEs
[1-2 years starting from the end of the project
(August 2016)]
Step 1 Step2
The Objective is to secure THINPAD NCIs a co-
development/license deal by 2018
the economic potential of the project
in house - SMEs Outlicensing to big Pharma